

Sub
C1
A2
4. (amended) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, acute and chronic bronchitis in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition comprising pharmaceutically effective amounts of active ingredients, said active ingredients consisting of carbetapentane tannate and guaifenesin.

✓
And add the following new claims:

A3
7. (new) The therapeutic composition of claim 2 wherein said tablet form contains from about 50 mg. to about 75 mg. of carbetapentane tannate and from about 100 mg. to about 300 mg. of guaifenesin.

8. (new) The therapeutic composition of claim 2 wherein said tablet form contains about 60 mg. of carbetapentane tannate and about 200 mg. of guaifenesin.

9. (new) The therapeutic composition of claim 3 wherein said suspension form contains from about 20 mg. to about 45 mg. of carbetapentane tannate and from about 50 mg. to about 150 mg. of guaifenesin, per 5 ml. of suspension.

10. (new) The therapeutic composition of claim 3 wherein said suspension form contains about 30 mg. of carbetapentane tannate and about 100 mg. of guaifenesin, per 5 ml. of suspension.

11. (new) The method of claim 5 wherein said tablet form contains from about 50 mg. to about 75 mg. of carbetapentane tannate and from about 100 mg. to about 300 mg. of guaifenesin.

12. (new) The method of claim 5 wherein said tablet form contains about 60 mg. of carbetapentane tannate and about 200 mg. of guaifenesin.

13. (new) The method of claim 6 wherein said suspension form contains from about 20 mg. to about 45 mg. of carbetapentane tannate and from about 50 mg. to about 150 mg. of guaifenesin, per 5 ml. of suspension.

14. (new) The method of claim 6 wherein said suspension form contains about 30 mg. of carbetapentane tannate and about 100 mg. of guaifenesin, per 5 ml. of suspension.

“Version with markings to show changes made.” M.P.E.P §714

1. (amended) Therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from [such as] the common cold, bronchial asthma, acute and chronic bronchitis in warm-blooded animals in need of such treatment said compositions comprising [of] pharmaceutically effective amounts of active ingredients, said active ingredients consisting of carbetapentane tannate and guaifenesin.

4. (amended) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, acute and chronic bronchitis in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition[s] [consisting essentially of] comprising pharmaceutically effective amounts of active ingredients, said active ingredients consisting of carbetapentane tannate and guaifenesin.